Valneva SE (VALN) Current Leases (2020 - 2026)
Valneva SE (VALN) posted Current Leases of $3.2 million for Q1 2026, up 0.61% sequentially from $3.2 million in Q4 2025, and up 12.99% YoY from $2.8 million in Q1 2025.
Analysis
Valneva SE (VALN) Current Leases (2020 - 2026) Analysis & Trends
Valneva SE has reported Current Leases for 7 years, with the latest figure at $3.2 million in Q1 2026.
- Quarterly Current Leases rose 12.99% year-over-year to $3.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.2 million (up 12.99% YoY) and the FY2025 annual result came in at $3.2 million, up 17.45% from the prior year.
- Current Leases climbed to $3.2 million in Q1 2026 per VALN's latest filing, from $3.2 million in the prior quarter.
- Over five years, Current Leases peaked at $28.2 million in Q2 2023 and troughed at $2.7 million in Q4 2024.
- A 5-year average of $8.8 million and a median of $3.1 million in 2022 frame the typical range for Current Leases.
- The sharpest annual moves came in 2023 and 2024: Current Leases surged 793.16% in 2023, then slumped 89.74% in 2024.
- Over 5 years, Current Leases stood at $25.9 million in 2022, then sank by 88.05% to $3.1 million in 2023, then decreased by 13.48% to $2.7 million in 2024, then rose by 18.97% to $3.2 million in 2025, then climbed by 0.61% to $3.2 million in 2026.
- According to Business Quant data, Current Leases over the past three periods registered $3.2 million, $3.2 million, and $3.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 11.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 16.75 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 21.95 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 45.93 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Valneva SE | 578.54 Mn | 437.28 Mn | 1.86 Mn | 3.17 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.17 Mn |
| Mar 31, 2026 | 3.21 Mn |
| Dec 31, 2025 | 3.19 Mn |
| Sep 30, 2025 | 3.13 Mn |
| Jun 30, 2025 | 3.00 Mn |
| Mar 31, 2025 | 2.84 Mn |
| Dec 31, 2024 | 2.68 Mn |
| Sep 30, 2024 | 2.92 Mn |
| Jun 30, 2024 | 2.90 Mn |
| Mar 31, 2024 | 2.91 Mn |
| Dec 31, 2023 | 3.10 Mn |
| Sep 30, 2023 | 28.08 Mn |
| Jun 30, 2023 | 28.25 Mn |
| Mar 31, 2023 | 27.68 Mn |
| Dec 31, 2022 | 25.93 Mn |
| Sep 30, 2022 | 3.14 Mn |
| Jun 30, 2022 | 3.19 Mn |
| Dec 31, 2021 | 3.59 Mn |
| Dec 31, 2020 | 3.21 Mn |